Volume 10 - Issue 6 - June 2013
Editor's Corner »
FDA Approval of Percutaneous EVAR
The US Food and Drug Administration has approved 21-French and smaller endovascular aneurysm repair (EVAR) systems to include percutaneous EVAR (PEVAR) based on the outcomes of the first prospective, multicenter, randomized PEVAR trial. The new on-label indication could accelerate adoption.
Case Files by Dr. George »
Retrograde Use of Re-Entry Catheter for Revascularization of Superficial Femoral Artery Chronic Total Occlusion
The authors present a case of endovascular revascularization of a chronic total occlusion via retrograde use of a re-entry catheter, which allows an alternative strategy for revascularization when antegrade approaches fail.
Clinical Review »
Endovascular Therapy for Treatment of Resistant Hypertension: Emerging Controversies and Technical Evolution
Prairie Cardiovascular Consultants, Springfield, Illinois
Despite encouraging early observations of renal denervation for treatment-resistant hypertension, recent reports in larger patient cohorts have suggested higher than initially reported nonresponder rates. Industry has responded with rapid device iteration, applying different energy sources and simpler catheter designs. Emerging evidence from small, uncontrolled trials continues to explore new potential applications.
Clinical Images »
Giant Abdominal Aortic Aneurysm
1Massachusetts General Hospital, Boston, Massachusetts, 2North Shore Medical Center, Salem, Massachusetts, 3Signature Healthcare, Brockton Hospital, Brockton, Massachusetts
The authors describe a case of asymptomatic giant AAA that measured 14 cm in diameter.
Editorial Commentary »
Endovascular Therapy: A Game-Changing Treatment for Resistant Hypertension
From St. Luke’s Medical Center, Phoenix, Arizona.
Transcatheter renal denervation has the potential to treat patients with not only hypertension but also renal insufficiency, congestive heart failure, diabetes mellitus, obesity, sleep apnea, and glucose intolerance.
Interview »
Application and Benefit of the TruePath CTO Device: An Interview With John Laird, MD
The TruePath CTO Device for chronic total occlusion (Boston Scientific), which has a diamond-coated distal tip that spins at 13,000 revolutions per minute, can help to break through extremely calcified lesions.
